These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 17335002)

  • 21. Early improvements in anxiety, depression, and anger/hostility symptoms and response to antidepressant treatment.
    Farabaugh A; Sonawalla S; Johnson DP; Witte J; Papakostas GI; Goodness T; Clain A; Baer L; Mischoulon D; Fava M; Harley R
    Ann Clin Psychiatry; 2010 Aug; 22(3):166-71. PubMed ID: 20680189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. If everyone were on Prozac...
    Gupta S
    Time; 2003 Jan; 161(3):81. PubMed ID: 12545568
    [No Abstract]   [Full Text] [Related]  

  • 23. Fluoxetine in adolescents with major depression and an alcohol use disorder: an open-label trial.
    Cornelius JR; Bukstein OG; Birmaher B; Salloum IM; Lynch K; Pollock NK; Gershon S; Clark D
    Addict Behav; 2001; 26(5):735-9. PubMed ID: 11676382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pharmacotherapy of depressive illness in adolescents: an open-label comparison of fluoxetine with imipramine-treated historical controls.
    Strober M; DeAntonio M; Schmidt-Lackner S; Pataki C; Freeman R; Rigali J; Rao U
    J Clin Psychiatry; 1999 Mar; 60(3):164-9. PubMed ID: 10192591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety.
    De Nayer A; Geerts S; Ruelens L; Schittecatte M; De Bleeker E; Van Eeckhoutte I; Evrard JL; Linkowski P; Fossion P; Leyman S; Mignon A
    Int J Neuropsychopharmacol; 2002 Jun; 5(2):115-20. PubMed ID: 12135535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder.
    Menza MA; Dobkin RD; Marin H
    J Clin Psychopharmacol; 2007 Apr; 27(2):207-10. PubMed ID: 17414231
    [No Abstract]   [Full Text] [Related]  

  • 27. Fluoxetine: new indication. Depression in children: too many uncertainties.
    Prescrire Int; 2008 Oct; 17(97):186-7. PubMed ID: 19534039
    [No Abstract]   [Full Text] [Related]  

  • 28. Once-daily venlafaxine XR compared with fluoxetine in outpatients with depression and anxiety.
    Judge R; Wagner BE
    J Clin Psychiatry; 1999 Nov; 60(11):795-6. PubMed ID: 10584775
    [No Abstract]   [Full Text] [Related]  

  • 29. Effectiveness of fluoxetine and doxepin in treatment of melancholia in depressed patients.
    Sandor P; Baker B; Irvine J; Dorian P; McKessok D; Mendlowitz S
    Depress Anxiety; 1998; 7(2):69-72. PubMed ID: 9614594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
    Pelissolo A
    Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Possible serotonin syndrome with trazodone addition to fluoxetine.
    George TP; Godleski LS
    Biol Psychiatry; 1996 Mar; 39(5):384-5. PubMed ID: 8704074
    [No Abstract]   [Full Text] [Related]  

  • 32. Fluoxetine versus other types of pharmacotherapy for depression.
    Magni LR; Purgato M; Gastaldon C; Papola D; Furukawa TA; Cipriani A; Barbui C
    Cochrane Database Syst Rev; 2013 Jul; (7):CD004185. PubMed ID: 24353997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paxil (paroxetine) lifts depression, lowers associated anxiety symptoms.
    Adv Nurse Pract; 1997 Oct; 5(10):71. PubMed ID: 9459990
    [No Abstract]   [Full Text] [Related]  

  • 34. Experiential Avoidance Predicts Persistence of Major Depressive Disorder and Generalized Anxiety Disorder in Late Adolescence.
    Mellick WH; Mills JA; Kroska EB; Calarge CA; Sharp C; Dindo LN
    J Clin Psychiatry; 2019 Oct; 80(6):. PubMed ID: 31644841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.
    Goodyer IM; Dubicka B; Wilkinson P; Kelvin R; Roberts C; Byford S; Breen S; Ford C; Barrett B; Leech A; Rothwell J; White L; Harrington R
    Health Technol Assess; 2008 May; 12(14):iii-iv, ix-60. PubMed ID: 18462573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: a single-blind, randomized clinical trial.
    Taner E; Demir EY; Cosar B
    Adv Ther; 2006; 23(6):974-87. PubMed ID: 17276965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of fluvoxamine and fluoxetine in the treatment of major depression.
    Rapaport M; Coccaro E; Sheline Y; Perse T; Holland P; Fabre L; Bradford D
    J Clin Psychopharmacol; 1996 Oct; 16(5):373-8. PubMed ID: 8889909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Personality changes during antidepressant treatment.
    Hruby R; Nosalova G; Ondrejka I; Preiss M
    Psychiatr Danub; 2009 Mar; 21(1):25-32. PubMed ID: 19270618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluoxetine versus amitriptyline in the treatment of major depression with associated anxiety (anxious depression): a double-blind comparison.
    Versiani M; Ontiveros A; Mazzotti G; Ospina J; Dávila J; Mata S; Pacheco A; Plewes J; Tamura R; Palacios M
    Int Clin Psychopharmacol; 1999 Nov; 14(6):321-7. PubMed ID: 10565798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is anxious-agitated major depression responsive to fluoxetine? A double-blind comparison with amitriptyline.
    Marchesi C; Ceccherininelli A; Rossi A; Maggini C
    Pharmacopsychiatry; 1998 Nov; 31(6):216-21. PubMed ID: 9930635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.